SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development
CHINO HILLS, CA / ACCESS Newswire / June 4, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, health and wellness solutions, proudly announces the appointment of Dr. Lucia Piccotti, PhD, EMBA, as a key member of our team. Dr. Piccotti will serve on the advisory board, advising on the development of cutting-edge cosmeceuticals and personal health products utilizing SOHM's cutting-edge technological advancements.
Dr. Piccotti is a distinguished biomedical scientist and strategic business leader, bringing over a decade of expertise in blending scientific research with entrepreneurial innovation. Her career has taken her through pivotal roles in both Fortune 500 companies and dynamic biotech startups, where she has excelled in translating complex biomedical concepts into impactful consumer products and business strategies.
Most recently, Dr. Piccotti served as Senior Director of Strategic Innovation at Kiromic Biopharma, a biotechnology company at the forefront of cell therapies for cancer. Her contributions were instrumental in navigating the company's growth through the critical phases of pre-IPO and post-IPO operations. Notably, she led innovative initiatives that utilized exosome technologies for skin health, showcasing her extensive knowledge and versatility in both therapeutic and consumer health applications.
In addition to her role at Kiromic, Dr. Piccotti is the founder of Iguvia LLC, a consulting firm that specializes in cosmeceuticals and health products. Since 2018, she has directed multiple projects focused on phytoextract-based topical applications, drawing on her in-depth expertise in skin health and bioactive formulation.
Earlier in her career, Dr. Piccotti was a Lead Scientist at Kimberly-Clark Corporation, where she advanced biomedical research and product development in the personal care and cosmeceutical sectors. Her innovative work has resulted in numerous patents and industry-recognized advancements, particularly in the use of phytoextracts and topical formulations.
Dr. Piccotti's impressive track record includes managing cross-functional teams and complex research studies, as well as collaborating with various departments, including Marketing and Regulatory Affairs. Her extensive network within the medical community, including connections with top institutions like the University of Texas and MD Anderson Cancer Center, positions her uniquely to drive SOHM Inc.'s growth and innovation in the industry.
'With Dr. Piccotti on board, we are poised to elevate our approach to cosmeceuticals and personal health products,' said David Aguilar, COO of SOHM Inc. 'Her strategic thinking and innovative mindset will significantly enhance our capabilities and ensure we continue to deliver high-quality solutions that meet the evolving needs of consumers.'
Dr. Piccotti graduated with a PhD in Biochemistry, where her thesis focused on liposomal delivery of anionic phospholipids to support mitochondrial bioenergetics, with implications for cellular aging. She also holds an MS in Chemistry with a thesis in Synthetic Organic Chemistry, and an Executive MBA, demonstrating her commitment to both scientific excellence and business leadership. Her collaborative leadership style and entrepreneurial spirit will be invaluable as she helps SOHM navigate the complexities of the cosmeceutical market.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: [email protected]
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Century Casinos, Inc. (CNTY): A Bull Case Theory
We came across a bullish thesis on Century Casinos, Inc. (CNTY) on The Hermit's Substack. In this article, we will summarize the bulls' thesis on CNTY. Century Casinos, Inc. (CNTY)'s share was trading at $1.99 as of 29th May. CNTY's trailing and forward P/E were 17.08 and 19.16, respectively, according to Yahoo Finance. Copyright: sainaniritu / 123RF Stock Photo Century Casinos' long-established operations in Colorado offer a clear window into the company's disciplined and founder-led approach to asset management. On a recent site tour through the western and midwestern U.S., including stops in Nevada, Arizona, New Mexico, Colorado, and Nebraska, the focus centered on Century's legacy properties in Cripple Creek and Central City—its first acquisitions dating back to 1996 and 2006, respectively. These casinos, with nearly three decades of operational continuity, reflect the founding vision of Erwin Haitzmann and Peter Hoetzinger and serve as operating templates for Century's broader portfolio. Unlike newer properties that prioritize revenue growth, the Colorado locations are highly optimized for cost control, acting more as dependable cash flow generators than aggressive growth engines. This disciplined structure enables Century to fuel expansion in other markets, such as their recent acquisition in Sparks–Reno, Nevada. Vice President Ahmad Ahmad expressed optimism for the region, noting that while the properties are smaller in scale, they punch above their weight in profitability. The site visit involved in-depth conversations with local staff and patrons, offering a qualitative perspective on service standards, food and beverage quality, and hotel experience. Special attention was paid to room cleanliness and hospitality, with a hospitality-savvy associate applying a thorough checklist to assess guest accommodations. The hands-on, grassroots evaluation provided more than just operational insights—it highlighted how culture and team partnerships enhance the investment process. Overall, Century's Colorado properties underscore a strategic foundation of fiscal prudence, reliable cash flow, and executional consistency that support its broader expansion story. Century Casinos, Inc. (CNTY) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 9 hedge fund portfolios held CNTY at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CNTY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
21 minutes ago
- Yahoo
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): 'It Doesn't Make Any Money'
We recently published a list of . In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses. When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said: 'You know, look, it doesn't make any money. I've been waiting for it to do something, break out. I just don't know if it has the horses.' A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab. Arrowhead Pharmaceuticals (NASDAQ:ARWR) develops RNA-based treatments for a wide range of hard-to-treat diseases, with multiple drug candidates in clinical trials targeting conditions such as cardiovascular disorders, liver disease, pulmonary illness, and rare genetic disorders. Additionally, in 2019, Cramer said the following about the company: 'I looked at Arrowhead recently and I didn't see that much. You know, everyone's so excited about it. I don't get that. I have been saying that it's absolutely O.K. to own stocks that have to do with slicing and dicing and genes, but I'm not gonna endorse it for anything other than speculation.' For context, since the above comment was aired, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock declined more than 75%. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Guess? Q1 Loss Narrower Than Expected, Revenues Up 9% Y/Y
Guess?, Inc. GES reported first-quarter fiscal 2026 results, wherein the top line increased year over year and surpassed the Zacks Consensus Estimate. While the bottom line fared better than the Zacks Consensus Estimate, it declined from the prior-year reported figure. The sales growth was primarily driven by the acquisition of rag & bone (concluded in April 2024). The company also updated its full-year guidance. Guess? reported adjusted loss of 44 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 70 cents. However, the bottom line deteriorated from an adjusted loss of 27 cents in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Guess?, Inc. price-consensus-eps-surprise-chart | Guess?, Inc. Quote Net revenues amounted to $647.8 million, up 9% year over year, surpassing the consensus mark of $631 million. On a constant-currency (cc) basis, net revenues rose 12%. The strong performance was driven by the rag & bone acquisition and positive momentum in the wholesale businesses across Europe and the Americas. Gross margin contracted to 39.9% from 41.9% reported in the year-ago quarter. As a percentage of sales, adjusted SG&A expenses increased to 44% from 43.2% in the prior-year loss from operations was $25.8 million compared with a loss of $7.7 million in the year-ago quarter. Adjusted operating margin declined to negative 4% from negative 1.3% in the same-period last year. This decline was primarily due to increased expenses, including higher advertising, store-related costs and performance-based compensation, as well as the unfavorable impact of business mix and currency. These pressures were partially offset by contributions from newly acquired businesses. Revenues in the Americas Retail segment rose 9% in U.S. dollars and 12% at cc. However, retail comparable sales, including e-commerce, declined 11% in U.S. dollars and 9% at cc. The operating margin in the segment was negative 10.5%, down 3.3% year over year. This decline was caused by the adverse effects of negative retail comparable sales, increased markdowns and higher expenses, including increased store costs, partially offset by the impact of newly acquired Wholesale revenues soared 63% on a reported basis and 70% at cc. The segment's operating margin fell to 19.9%, down 2.8% year over year, due to the impact of newly acquired businesses and increased expenses, partially offset by the favorable impact of elevated Europe segment's revenues increased 8% on a reported basis and 9% at cc. Retail comp sales (including e-commerce) decreased 4% on a reported basis and 3% at cc. The segmental operating margin was negative 2.9%, down 2.7% year over year, due to higher expenses, including elevated advertising and store costs, and an unfavorable currency revenues decreased 20% on a reported basis and 16% at cc. Retail comp sales (including e-commerce) dropped 24% and 20% on a reported basis and at cc, respectively. The operating margin in the segment was negative 3.1%, down 8.2% year over year. This downside was due to reduced revenues, partially offset by lower revenues decreased 14% on a reported basis and at cc. Segmental operating margin was 92.1% compared with 92% in the year-ago quarter. The company exited the quarter with cash and cash equivalents of $151.2 million and long-term debt and finance lease obligations of nearly $241.7 million. Stockholders' equity was around $483.6 cash used in operating activities for the fiscal first quarter ended May 3, 2025, was negative $73.4 million. Free cash flow for the same period amounted to negative $96.4 million. For fiscal 2026, free cash flow is expected to be $55 announced a quarterly dividend of 30 cents per share, payable on July 3, 2025, to its shareholders on record as of June 18. For fiscal 2026, Guess? now expects revenues to grow between 5.5% and 7.4%, an increase from its prior outlook of 3.9% to 6.2%.The adjusted operating margin is projected in the range of 4.4% to 5.1%, which is slightly down from the previous estimate of 4.5% to 5.4%. The GAAP operating margin is now forecasted between 3.9% and 4.6%, down from the earlier range of 4.3% to 5.2%.Management anticipates adjusted earnings per share (EPS) of $1.32 to $1.64 compared with the prior projection of $1.32 to $1.76 and actual EPS of $1.96 in fiscal 2025. On a GAAP basis, EPS is now expected to be in the range of 87 cents to $1.11, down from the previous outlook of $1.03 to $1.37. The metric was 77 cents per share in fiscal the second quarter of fiscal 2026, Guess? expects revenue growth of 2.9% to 4.7%. Adjusted EPS is expected to range from 11-21 cents, while GAAP EPS is projected between 11 cents and 18 of this Zacks Rank #4 (Sell) company have risen 3.7% in the past three months against the industry's 2.1% decline. Image Source: Zacks Investment Research Urban Outfitters, Inc. URBN offers lifestyle products and services. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks Zacks Consensus Estimate for Urban Outfitters' current fiscal-year earnings and sales indicates growth of 20.9% and 8%, respectively, from the year-ago period's reported figures. URBN delivered a trailing four-quarter average earnings surprise of 29%.Canada Goose Holdings Inc. GOOS designs, manufactures and sells performance luxury apparel for men, women, youth, children and babies. It carries a Zacks Rank of 2 (Buy) at present. GOOS delivered a trailing four-quarter average earnings surprise of 57.2%.The Zacks Consensus Estimate for Canada Goose's current fiscal-year earnings and sales implies a decline of 10% and 2.9%, respectively, from the year-ago Inc. BIRD manufactures and sells footwear and apparel products for men and women in the United States and internationally, flaunting a Zacks Rank #2. BIRD delivered a trailing four-quarter earnings surprise of 21.3%, on Zacks Consensus Estimate for Allbirds' current fiscal-year earnings indicates growth of 16.1%, from the year-ago period's reported figures. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Urban Outfitters, Inc. (URBN) : Free Stock Analysis Report Guess?, Inc. (GES) : Free Stock Analysis Report Canada Goose Holdings Inc. (GOOS) : Free Stock Analysis Report Allbirds, Inc. (BIRD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
